BARRY W. LIECHTY, M.D.

Plain English
This study looked at a patient with a rare and aggressive type of brain tumor called WHO-3 meningioma, which had spread to the liver. The treatment used was Yttrium-90 radioembolization, and it successfully targeted the liver metastases. The findings are important because they offer a new option for treating a cancer that currently lacks established guidelines. Who this helps: This helps patients with rare brain tumors that have spread to the liver.

Plain English
This study looked at how a special type of PET scan called [Ga68]DOTATATE PET can help identify schwannomas, a type of tumor that can occur in the brain and neck. The researchers found that the schwannomas showed low levels of activity on the PET scan, with an average measurement of 1.6, which is much lower than what is seen in similar tumors like meningiomas. This matters because it means that the PET scan can help doctors distinguish schwannomas from other tumors that look similar on MRI, reducing the need for invasive procedures. Who this helps: This helps doctors and patients by providing a non-invasive way to better diagnose schwannomas.

Plain English
This study looked at how a treatment called bevacizumab affects high-grade meningiomas, aggressive brain tumors, using a specific type of imaging called [68Ga]-DOTATATE PET. The researchers found that 67% of the tumor sites in three patients showed a significant drop in activity after the treatment, while control patients with similar tumors showed no change. This is important because it suggests that [68Ga]-DOTATATE PET might help track how well treatment is working in ways that regular MRI scans do not. Who this helps: This benefits patients with high-grade meningioma and their doctors by providing a better way to monitor treatment response.

Plain English
This study looked at how a specialized imaging method called PET/MRI, combined with a new radioactive tracer called [Cu64]DOTATATE, can help surgeons find and remove meningiomas, which are common brain tumors. The researchers found that the technique allowed them to detect tumor activity that was 10 times higher than surrounding tissue and showed a 50% decrease in activity after part of the tumor was removed. This is important because accurate removal of these tumors can lead to better survival rates and overall patient outcomes. Who this helps: This benefits patients with meningiomas and their doctors by improving surgical results.

Plain English
This study examined a specific protein called SSTR2 in pituitary tumors and normal pituitary tissue to see how it varies based on age, sex, and hormone levels. Researchers analyzed samples from 271 tumors and 20 normal controls, finding that while different types of tumors showed varying amounts of SSTR2, females generally had higher levels than males. Understanding these patterns is important because they could help doctors use imaging techniques targeting SSTR2 to improve treatment for certain pituitary tumors. Who this helps: This benefits patients with pituitary tumors and their doctors.

Plain English
This study examined the effectiveness of a new imaging technique that combines two types of PET scans (FMISO and FLT) to assess brain tumors called glioblastomas. Researchers found that all 13 tumor lesions in the eight patients studied were successfully imaged, showing an average score of 1.72, which indicates a presence of both hypoxia and cell growth in the tumors. The findings suggest that this method can give doctors better insights into tumor conditions, which can help improve the effectiveness of treatments like radiation therapy. Who this helps: This benefits patients with glioblastoma and doctors treating these aggressive brain tumors.

Plain English
This study looked at patients with WHO grade 2 meningiomas who had their tumors fully removed and were monitored over time to see how well they did after surgery. The researchers found that patients who had their surgery confirmed with a special imaging technique called DOTATATE PET/MRI had a 90% chance of not experiencing tumor progression after 5 years, while those assessed only by regular MRI had a 67% chance. This is important because it shows that using DOTATATE PET/MRI can lead to better outcomes for patients and may help avoid unnecessary additional treatments like radiation. Who this helps: This helps patients with WHO grade 2 meningiomas and their doctors by providing clearer guidance on treatment options after surgery.

Plain English
The study focused on using a special imaging technique called [F18]-Fluciclovine PET/MRI to determine whether patients with glioblastoma (a type of brain cancer) are experiencing true tumor growth or just treatment-related changes in their condition. Researchers looked at scans from 36 patients and found that those with true tumor progression had a significantly higher level of a specific measure (SUVmax) compared to those with treatment-related changes (8.73 versus 3.71). This method showed strong accuracy, correctly identifying tumor progression 86% of the time. Who this helps: This research benefits patients with glioblastoma by providing doctors with better tools to assess their condition.

Plain English
This study looked at how low oxygen levels in the brain affect the growth of glioma stem cells, which are a type of cancer cell in brain tumors. Researchers created a model using brain-like structures (called organoids) and discovered that poor oxygen and stress in these structures help cancer cells grow faster over time. They found that certain brain cells, called astrocytes, release substances that encourage this cancer growth, particularly in older patients and those with chronic oxygen shortage. Who this helps: This research benefits patients with glioblastoma, their doctors, and researchers looking to better understand and treat brain tumors.

Plain English
This study looked at two types of aggressive brain tumors called WHO grade 3 meningiomas: those that are newly diagnosed (de novo) and those that have progressed from a previously treated tumor (secondary-progressive). Researchers found that patients with secondary-progressive meningiomas had fewer months without disease worsening (4.8 months) compared to the de novo group (37.7 months), and they also underwent more surgeries (4.1 surgeries per patient vs. 1.6). These findings are important because they highlight the need for different treatment approaches for these two groups and show how advanced imaging can help doctors better understand and manage these tumors. Who this helps: This helps patients with meningiomas and their doctors in choosing effective treatment plans.

Plain English
This study looked at a new test called the Idylla assay, which quickly checks for mutations in IDH1 and IDH2 genes in brain tumors known as gliomas. The researchers found that the Idylla assay has a 97% accuracy rate compared to a more traditional method called next-generation sequencing, and it can deliver results in just a few hours instead of days. This rapid testing matters because knowing a patient’s mutation status can significantly affect treatment decisions and outcomes. Who this helps: This helps doctors and patients with glioma by providing faster, more accurate information for treatment planning.

Plain English
Researchers looked at using a special imaging technique called [18F]-Fluoroestradiol (FES) PET to help evaluate patients with estrogen receptor-positive breast cancer that may have spread to the brain. In a study of seven patients, they found that 94% of cancerous brain lesions showed up as positive on the FES scan, while all lesions from past radiation treatment were negative, indicating FES could effectively differentiate between active cancer and treatment effects. This is important because it could lead to better monitoring and management of brain metastases in these patients. Who this helps: This helps patients with estrogen receptor-positive breast cancer and their doctors in making more informed treatment decisions.

Plain English
This study looked at patients with pineal cysts—fluid-filled sacs located in the brain—who had troubling symptoms but no obvious signs of-related brain swelling (hydrocephalus) on standard scans. Researchers found that out of 50 patients, 4 had serious symptoms like severe headaches and fainting, despite appearing stable on typical images. After a specific surgery to treat these cysts, all patients saw their symptoms completely go away over an average follow-up of about 21 months. Who this helps: This research benefits patients with pineal cysts and their doctors by identifying high-risk cases that need careful attention.

Plain English
This study focused on two cases of a common type of brain cancer in children called pilocytic astrocytoma, which usually grows slowly. In one case, a 12-year-old boy's tumor shrank after treatment with a specific drug, while in another case, a 6-year-old boy's tumor showed complex changes that required advanced testing to understand fully. The findings highlight how important it is to use deep genetic testing to find the best treatment options for these cancers, which can greatly improve the outcomes for young patients. Who this helps: This helps pediatric cancer patients and their doctors.

Plain English
This study looked at a rare type of brain tumor called polymorphous low-grade neuroepithelial tumor of the young (PLNTY) that can look like a more aggressive brain cancer known as high-grade glioma (HGG). The researchers presented a case of a 59-year-old woman with PLNTY who showed no tumor progression after 15 months, contrasting with adult HGG patients who had the same genetic marker but experienced a median survival of only 15 months. These findings highlight the importance of accurately diagnosing PLNTY, as it has a much better outlook than tumors that appear more aggressive. Who this helps: This research helps doctors and patients by improving understanding of brain tumors and their treatments.

Plain English
This study looked at how well the cancer treatment axicabtagene ciloleucel works in patients with central nervous system lymphoma (SCNSL) and/or HIV, who were previously excluded from major clinical trials. Out of 14 patients treated, 58% showed a complete response to the treatment, and 32% experienced severe side effects called neurotoxicity, which are similar to what others have reported in broader patient groups. This research highlights that axicabtagene ciloleucel may be a valuable treatment option for patients with SCNSL, suggesting it should be made available to them. Who this helps: Patients with central nervous system lymphoma and HIV.

Plain English
This study looked at how well different methods using a specific type of brain imaging, called [Ga]-DOTATATE PET/MRI, can identify meningioma tumors and distinguish them from changes caused by treatment. Researchers examined 62 patients and found that the best method, using the SUVR relative to the superior sagittal sinus, detected meningiomas with a sensitivity of 86.1% and an optimal threshold of 3.2. These findings are important because they improve diagnosis, helping doctors make more accurate assessments of patients suspected of having recurring meningioma. Who this helps: This research benefits patients with meningioma and their doctors.

Plain English
This study looked at a rare brain tumor in a four-year-old girl where researchers found a specific genetic fusion called YAP1-MAML2. This was significant because it had not been previously linked to schwannomas, which are tumors that usually result from a different genetic change known as NF2 inactivation. The findings highlight the importance of genetic testing in young patients with similar tumors, as identifying these unusual genetic changes can help doctors make accurate diagnoses and determine appropriate treatment options. Who this helps: This helps pediatric patients with brain tumors and their doctors.

Plain English
This study looked at a new method for diagnosing brain tumors by using targeted DNA and RNA sequencing, which can find cancer-related changes more effectively than traditional techniques. The researchers found that this new sequencing method was significantly better at detecting specific mutations, such as in the IDH1/2 and TP53 genes, and predicting important genetic changes with over 90% accuracy. This is important because it could lead to quicker and more precise diagnoses, ultimately improving treatment options for patients with brain tumors. Who this helps: This helps patients with brain tumors and their doctors by providing more accurate and timely diagnoses.

Plain English
This study looked at how well machine learning (ML) models can predict a specific genetic mutation in brain tumors, called IDH mutation, by analyzing tissue samples under a microscope. Researchers found that while human experts were better overall at predicting these mutations, combining their assessments with ML predictions led to even better results, achieving an accuracy close to that of two experts working together (0.921 compared to 0.920). This is important because it shows how technology can enhance the accuracy of tumor diagnosis, potentially leading to better treatment decisions for patients. Who this helps: This benefits patients with infiltrating gliomas and their healthcare providers.

Plain English
Researchers studied brain tissues from 13 people who died from COVID-19 to understand how the disease affects the brain. They found that all 13 samples showed signs of damage in the brain's blood vessel cells, with an average of 4.3 damaged cells observed in a specific viewing area. This is important because it highlights that damage to these cells is a key part of what makes COVID-19 so harmful, which could help in diagnosing the disease and understanding its effects on the nervous system. Who this helps: This helps doctors and researchers understand how to better diagnose and treat COVID-19-related brain complications.

Plain English
This study looked at how the timing of radiosurgery (SRS) affects the chance of brain metastases returning after surgery. Researchers found that if patients received SRS within 4 weeks after surgery, only 2.3% experienced a local recurrence, compared to 23.6% for those who received it later (more than 4 weeks). This matters because getting SRS sooner significantly reduces the risk of cancer coming back in the same area. Who this helps: This helps patients with brain metastases and their doctors by highlighting the importance of timely treatment.

Plain English
This study looked at how long patients with brain metastases waited to receive a specific type of radiation treatment called stereotactic radiosurgery (SRS) after their surgery. Among 159 patients, those who received SRS within 4 weeks had a low recurrence rate of just 2.3%, while those who received it after 8 weeks faced a much higher rate of 48.5%, similar to patients who never received the treatment. This matters because timely delivery of SRS significantly improves patient outcomes, but many patients either experience delays or never receive the treatment at all. Who this helps: This research benefits patients with brain metastases by highlighting the importance of timely treatment and addressing delays.

Plain English
This study looked at how well patients with a type of brain tumor called atypical meningioma do when they receive radiation treatment immediately after surgery compared to those who are simply monitored after surgery. The researchers found that for patients whose tumors were fully removed (gross total resection), those who received radiation had a much higher chance of not having the tumor come back after 3 years (100% with radiation vs. 63% without). However, there was no significant difference in overall survival between the two groups. Who this helps: This information benefits patients with atypical meningiomas and their doctors by providing insights on treatment options after surgery.

Plain English
This study looked at meningiomas, which are the most common type of brain tumor, to see if there is a link between how much blood they have (vascularity) and the expression of a specific receptor (SSTR2). Researchers found a strong connection in higher-grade tumors (WHO-2 and WHO-3) but not in lower-grade tumors (WHO-1), with correlation values over 0.8 indicating a significant relationship. Understanding this link could help better predict tumor behavior and guide treatment options. Who this helps: This benefits patients with meningiomas and their doctors by improving tumor assessment and management.

Plain English
This report describes a unique case where a patient with a clival chordoma, a type of tumor located at the base of the skull, experienced a significant reduction in tumor size without medical treatment. Initially, the tumor measured about 8.84 cm, but two months later, it shrank by 61.7% to approximately 3.38 cm. The patient took herbal supplements and animal oils, which might have played a role in this unexpected improvement. Who this helps: This information could benefit patients with chordomas and their doctors exploring treatment options.

Plain English
The study looked at a type of brain tumor called meningioma, specifically those that do not have a common receptor (SSTR2) that is usually targeted by imaging tests using a substance called Ga-DOTATATE. They found an atypical meningioma that showed very little uptake of Ga-DOTATATE, indicating it was SSTR2-negative, which means standard imaging may not be effective for these tumors. This matters because identifying the presence or absence of SSTR2 can significantly impact how doctors evaluate and treat these tumors. Who this helps: This helps patients with atypical meningiomas and their doctors by improving how these tumors are diagnosed and monitored.

Plain English
This study looked at how involvement of a brain area called the subventricular zone (SVZ) and certain genetic traits in lower grade gliomas (a type of brain tumor) can predict patient outcomes. Researchers found that while most SVZ involvement did not indicate worse outcomes, tumors with occipital SVZ involvement showed a much higher risk of progression and death—specifically, a 6.6 times greater risk of tumor progression and a 31.5 times greater risk of death. This information is crucial because it helps identify which patients might be at a higher risk for complications. Who this helps: This helps patients with lower grade gliomas and their doctors in making treatment decisions based on risk.

Plain English
Researchers studied a specific genetic mutation in the SCAPER gene that causes a type of vision loss called retinitis pigmentosa, which usually comes with other symptoms like learning disabilities and ADHD. They found this mutation in an 11-year-old boy who only experienced vision issues, specifically difficulty seeing at night, without any additional symptoms. This discovery shows that the SCAPER mutation can lead to vision loss alone, which expands the understanding of how this gene affects patients. Who this helps: This helps patients with retinitis pigmentosa and their families.

Plain English
This study looked at how a specialized imaging technique called [68Ga]-DOTATATE PET/MRI can help identify meningiomas, which are the most common type of brain tumors. In a group of 20 patients, this method was able to correctly confirm the presence of recurrent tumors in 17 patients, showing a significant difference between actual tumors and changes from previous treatments. This is important because it can improve how doctors diagnose and manage these tumors, especially when standard MRI results are unclear. Who this helps: This helps patients with meningiomas and their doctors by providing clearer imaging for better treatment decisions.

Plain English
The researchers studied how a special type of MRI, called dynamic contrast-enhanced MRI (DCE MRI), can provide important information about meningiomas (a type of brain tumor) that had been surgically removed and then treated with radiation. They looked at 14 patients with a total of 18 tumors and found that those with more aggressive tumors (indicated by a higher Ki-67 score) had lower blood flow and contrast absorption in the tumors. Specifically, patients with a Ki-67 score above 15% showed a significant decrease in blood volume and a slower wash-in rate of contrast compared to those with scores at or below 15%, which could help predict how quickly the tumors might progress. Who this helps: This research benefits patients with meningiomas by improving diagnosis and treatment planning.

Plain English
This study looked at a rare case of a type of brain tumor that developed from a benign cyst in the pineal area. The researchers found two separate lesions: one was a cyst, and the other was a cancer known as squamous cell carcinoma. They also did a genetic analysis of the tumor, which showed specific genetic changes. This information is important because it provides insights into how this rare cancer develops and may help improve diagnosis and treatment options in the future. Who this helps: Patients with rare brain tumors and their doctors.

Plain English
This study looked at specific tumors associated with neurofibromatosis types 1 and 2 (NF1 and NF2) to see if they expressed a protein called PD-L1, which helps tumors evade the immune system, and whether immune cells were present in the tumors. The researchers found that PD-L1 was present in a high percentage of these tumors: for example, 100% of plexiform neurofibromas and 70% of schwannomas tested positive for PD-L1. This is important because it indicates that tumors from NF patients may respond to new immunotherapy treatments, which could improve patient outcomes. Who this helps: Patients with neurofibromatosis type 1 and 2.

Plain English
This study looked at a specific chemical marker (H3K27me3) in brain tumors called meningiomas to see how it relates to the risk of the tumors coming back after treatment. Researchers found that in 194 out of 232 tumors, H3K27me3 was present, but when it was missing in tumor cells, it was linked to quicker tumor growth, with a significant association (p=0.009). The findings show that checking for H3K27me3 can help doctors better understand the aggressiveness of the tumor, particularly in cases that are classified as WHO grade II or borderline between grade I and II. Who this helps: This helps patients with meningiomas and their doctors by providing more information for treatment decisions.

Plain English
This study examined a rare type of lymphoma called primary dural extranodal marginal zone lymphoma (MZL) and reported a unique case of a patient who also had chronic lymphocytic leukemia (CLL). Researchers found 104 previous cases of dural MZL, but none had been reported alongside another lymphoma, making this case special. Understanding this condition is important because it helps doctors tailor treatments, which often include surgery and radiation, for better patient outcomes. Who this helps: This helps patients with rare lymphomas and their doctors.

Plain English
This study looked at patients with tuberous sclerosis complex, a condition that can cause epilepsy, to see if there were abnormal brain tissues called subependymal giant cell astrocytomas (SEGAs) within other brain lesions called cortical tubers. Out of 75 patients, three had SEGA tissue found in their resected tubers, and importantly, none of these patients had previously been treated with a specific drug (mTOR inhibitors) that can help manage their seizures. Two of these three patients showed good outcomes after surgery, which indicates that some patients with severe epilepsy might benefit from trying mTOR inhibitors before considering surgery. Who this helps: Patients with tuberous sclerosis complex and medication-resistant epilepsy.

Plain English
This study looked at a 73-year-old woman who had a history of cancer and developed brain lesions, along with vision problems and difficulty recognizing faces. The research found that her issues were due to inflammation caused by a condition linked to amyloid deposits in her brain, which was confirmed through a biopsy. After treatment with medication to suppress her immune system, her condition improved, highlighting the importance of recognizing this inflammation for proper diagnosis and treatment. Who this helps: This helps patients experiencing similar brain symptoms and their healthcare providers.

Plain English
This study looked at a rare type of tumor called epithelioid hemangioendothelioma (EHE) that can occur in the brain, specifically in a part called the suprasellar region. Researchers examined a case involving a 45-year-old woman who experienced worsening fatigue, sleepiness, and memory issues for six months before doctors found a large tumor in her brain and performed surgery to remove part of it. The findings indicate that EHE in the brain, although rare, can have a relatively good outcome after surgery, and that treatment options exist even when the tumor cannot be completely removed. Who this helps: This helps patients with similar brain tumors and their doctors in understanding treatment options and outcomes.

Plain English
This study looked at two patients who had colon cancer that first showed up as back problems caused by cancer spreading to their spine. In both cases, there were no signs of colon cancer until the cancer spread, reminding doctors that they shouldn’t completely rule out colon cancer just because a patient has bone issues. This is important because it encourages more careful diagnosis, leading to earlier detection and treatment of colon cancer. Who this helps: This helps patients who may have undiagnosed colon cancer that spreads to other parts of the body.

Plain English
This research focused on a compound called Nannocystin A, derived from a type of bacteria, that affects a protein important for cell growth. The study found that Nannocystin A can kill various cancer cells, and its effectiveness varies depending on the level of a specific protein (EF-1α) present in those cells. This is significant because it could lead to new cancer treatment options that are more targeted based on the cancer's specific characteristics. Who this helps: This helps cancer patients by potentially providing more effective treatment options tailored to their specific cancer type.

Plain English
This study looked at a natural compound called cyclomarin A to see how well it can fight malaria and tuberculosis. Researchers found that cyclomarin A effectively stops the growth of malaria-causing parasites, specifically targeting an enzyme called PfAp3Aase without affecting a similar enzyme in humans. This discovery is important because it highlights a new potential treatment path for malaria, with cyclomarin A having a unique way of working against these diseases. Who this helps: This benefits malaria patients and healthcare providers seeking new treatment options.

Plain English
This study looked at a new treatment method using a special type of bone material called polyethylene mesh-contained morcelized allograft (PMCMA) for managing spinal fractures. The researchers found that, while there are currently no detailed studies showing the results of this technique, it operates similarly to existing methods like vertebroplasty and kyphoplasty. Understanding how effective the PMCMA method is could be important for improving treatments for spinal fractures in patients with osteoporosis or similar conditions. Who this helps: Patients with vertebral compression fractures.